Menu
Search
|

Menu

Close
X

Odonate Therapeutics Inc ODT.OQ (NASDAQ Stock Exchange Global Select Market)

27.78 USD
-0.58 (-2.05%)
As of 4:48 PM BST
Previous Close 28.36
Open 28.36
Volume 10,869
3m Avg Volume 41,774
Today’s High 28.49
Today’s Low 27.78
52 Week High 43.61
52 Week Low 11.68
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-2.314
FY18
-3.634
FY17
-1.194
FY16
-0.116
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
--
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
--
14.55
LT Debt to Equity (MRQ)
vs sector
--
10.20
Return on Investment (TTM)
vs sector
--
14.48
Return on Equity (TTM)
vs sector
--
15.78

EXECUTIVE LEADERSHIP

Kevin Tang
Chairman of the Board, Chief Executive Officer, Since 2013
Salary: $1.00
Bonus: --
Jeff Vacirca
Vice Chairman of the Board, Since 2016
Salary: --
Bonus: --
Michael Hearne
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
John Lemkey
Chief Operating Officer, Since 2018
Salary: $200,000.00
Bonus: --
Joseph O'Connell
Chief Medical Officer, Since 2017
Salary: $353,300.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

4747 Executive Dr Ste 510
SAN DIEGO   CA   92121-3100

Phone: +1858.2003830

Odonate Therapeutics, Inc., formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC). The Company's tesetaxel can be administered orally with a low pill burden and dosing regimen. Taxanes destroy cancer cells by preventing them from entering mitosis and thereby leading to apoptosis (cell death).

SPONSORED STORIES